158 related articles for article (PubMed ID: 18997054)
1. Relationship between cancer type and impact of PET and PET/CT on intended management: findings of the national oncologic PET registry.
Hillner BE; Siegel BA; Shields AF; Liu D; Gareen IF; Hunt E; Coleman RE
J Nucl Med; 2008 Dec; 49(12):1928-35. PubMed ID: 18997054
[TBL] [Abstract][Full Text] [Related]
2. Impact of positron emission tomography/computed tomography and positron emission tomography (PET) alone on expected management of patients with cancer: initial results from the National Oncologic PET Registry.
Hillner BE; Siegel BA; Liu D; Shields AF; Gareen IF; Hanna L; Stine SH; Coleman RE
J Clin Oncol; 2008 May; 26(13):2155-61. PubMed ID: 18362365
[TBL] [Abstract][Full Text] [Related]
3. Impact of 18F-fluoride PET in patients with known prostate cancer: initial results from the National Oncologic PET Registry.
Hillner BE; Siegel BA; Hanna L; Duan F; Shields AF; Coleman RE
J Nucl Med; 2014 Apr; 55(4):574-81. PubMed ID: 24578240
[TBL] [Abstract][Full Text] [Related]
4. The National Oncologic PET Registry (NOPR): design and analysis plan.
Hillner BE; Liu D; Coleman RE; Shields AF; Gareen IF; Hanna L; Stine SH; Siegel BA
J Nucl Med; 2007 Nov; 48(11):1901-8. PubMed ID: 17942807
[TBL] [Abstract][Full Text] [Related]
5. Impact of (18)F-Fluoride PET on Intended Management of Patients with Cancers Other Than Prostate Cancer: Results from the National Oncologic PET Registry.
Hillner BE; Siegel BA; Hanna L; Duan F; Shields AF; Quinn B; Coleman RE
J Nucl Med; 2014 Jul; 55(7):1054-61. PubMed ID: 24819422
[TBL] [Abstract][Full Text] [Related]
6. Impact on Patient Management of [18F]-Fluorodeoxyglucose-Positron Emission Tomography (PET) Used for Cancer Diagnosis: Analysis of Data From the National Oncologic PET Registry.
Subramaniam RM; Shields AF; Sachedina A; Hanna L; Duan F; Siegel BA; Hillner BE
Oncologist; 2016 Sep; 21(9):1079-84. PubMed ID: 27401896
[TBL] [Abstract][Full Text] [Related]
7. PET-CT in recurrent head neck cancers: a study to evaluate impact on patient management.
Pantvaidya GH; Agarwal JP; Deshpande MS; Rangarajan V; Singh V; Kakade A; D'Cruz AK
J Surg Oncol; 2009 Oct; 100(5):401-3. PubMed ID: 19235784
[TBL] [Abstract][Full Text] [Related]
8. Sources and resources for oncologists to help answer the question: is PET/CT appropriate for my patient?
Karantanis D; Allen-Auerbach M; Czernin J
Hell J Nucl Med; 2012; 15(1):2-8. PubMed ID: 22413105
[TBL] [Abstract][Full Text] [Related]
9. Incidental PET/CT findings in the cancer patient: how should they be managed?
Beatty JS; Williams HT; Aldridge BA; Hughes MP; Vasudeva VS; Gucwa AL; David GS; Lind DS; Kruse EJ; McLoughlin JM
Surgery; 2009 Aug; 146(2):274-81. PubMed ID: 19628085
[TBL] [Abstract][Full Text] [Related]
10. Impact of 18F-FDG PET used after initial treatment of cancer: comparison of the National Oncologic PET Registry 2006 and 2009 cohorts.
Hillner BE; Siegel BA; Hanna L; Shields AF; Duan F; Gareen IF; Quinn B; Coleman RE
J Nucl Med; 2012 May; 53(5):831-7. PubMed ID: 22448033
[TBL] [Abstract][Full Text] [Related]
11. Intended versus inferred care after PET performed for initial staging in the National Oncologic PET Registry.
Hillner BE; Tosteson AN; Tosteson TD; Wang Q; Song Y; Hanna LG; Siegel BA
J Nucl Med; 2013 Dec; 54(12):2024-31. PubMed ID: 24221994
[TBL] [Abstract][Full Text] [Related]
12. Prospective comparison of [18F]fluorodeoxyglucose positron emission tomography and computed tomography in patients with melanoma with palpable lymph node metastases: diagnostic accuracy and impact on treatment.
Bastiaannet E; Wobbes T; Hoekstra OS; van der Jagt EJ; Brouwers AH; Koelemij R; de Klerk JM; Oyen WJ; Meijer S; Hoekstra HJ
J Clin Oncol; 2009 Oct; 27(28):4774-80. PubMed ID: 19720925
[TBL] [Abstract][Full Text] [Related]
13. Quantitative imaging in oncology patients: Part 2, oncologists' opinions and expectations at major U.S. cancer centers.
Jaffe TA; Wickersham NW; Sullivan DC
AJR Am J Roentgenol; 2010 Jul; 195(1):W19-30. PubMed ID: 20566776
[TBL] [Abstract][Full Text] [Related]
14. The impact of positron emission tomography (PET) on expected management during cancer treatment: findings of the National Oncologic PET Registry.
Hillner BE; Siegel BA; Shields AF; Liu D; Gareen IF; Hanna L; Stine SH; Coleman RE
Cancer; 2009 Jan; 115(2):410-8. PubMed ID: 19016303
[TBL] [Abstract][Full Text] [Related]
15. Practice-based evidence for the clinical benefit of PET/CT-results of the first oncologic PET/CT registry in Germany.
Pfannenberg C; Gueckel B; Wang L; Gatidis S; Olthof SC; Vach W; Reimold M; la Fougere C; Nikolaou K; Martus P
Eur J Nucl Med Mol Imaging; 2019 Jan; 46(1):54-64. PubMed ID: 30269155
[TBL] [Abstract][Full Text] [Related]
16. Integrated PET/CT and cancer imaging.
De Wever W; Coolen J; Verschakelen JA
JBR-BTR; 2009; 92(1):13-9. PubMed ID: 19358480
[TBL] [Abstract][Full Text] [Related]
17. PET/CT for the staging and follow-up of patients with malignancies.
Poeppel TD; Krause BJ; Heusner TA; Boy C; Bockisch A; Antoch G
Eur J Radiol; 2009 Jun; 70(3):382-92. PubMed ID: 19406595
[TBL] [Abstract][Full Text] [Related]
18. Early prediction of response to chemoradiotherapy for head and neck cancer: reliability of restaging with combined positron emission tomography and computed tomography.
Malone JP; Gerberi MA; Vasireddy S; Hughes LF; Rao K; Shevlin B; Kuhn M; Collette D; Tennenhouse J; Robbins KT
Arch Otolaryngol Head Neck Surg; 2009 Nov; 135(11):1119-25. PubMed ID: 19917925
[TBL] [Abstract][Full Text] [Related]
19. Clinical impact of capsule endoscopy on management of gastrointestinal disorders.
Ahmad NA; Iqbal N; Joyce A
Clin Gastroenterol Hepatol; 2008 Apr; 6(4):433-7. PubMed ID: 18325843
[TBL] [Abstract][Full Text] [Related]
20. Intended versus inferred management after PET for cancer restaging: analysis of Medicare claims linked to a coverage with evidence development registry.
Hillner BE; Tosteson TD; Tosteson AN; Wang Q; Song Y; Onega T; Hanna LG; Siegel BA
Med Care; 2013 Apr; 51(4):361-7. PubMed ID: 23481033
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
